Squarepoint
IOVA icon

Squarepoint’s Iovance Biotherapeutics IOVA Stock Holding History

Squarepoint’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,100
Closed -$224K – 3330
2021
Q3 		$224K Hold
9,100
– – ﹤0.01% 2417
2021
Q2 		$237K Hold
9,100
– – ﹤0.01% 2694
2021
Q1 		$288K Buy
+9,100
New +$377K ﹤0.01% 2437

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Squarepoint's IOVA Position: Q1 2026 in Review

Squarepoint increased its Iovance Biotherapeutics (IOVA) stake by 4,029% in Q1 2026, buying an estimated $3.22M and bringing the position to 1,032,168 shares worth $3.62M. The position accounts for ﹤0.01% of the portfolio, ranked #1745.

Squarepoint first reported a position in IOVA in Q3 2017 and has held it in 29 quarters since. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Squarepoint held 1,032,168 shares of Iovance Biotherapeutics worth $3.62M as of Q1 2026.
  • Squarepoint bought 1,007,167 Iovance Biotherapeutics shares in Q1 2026, an estimated $3.22M.
  • Iovance Biotherapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #1745 holding.
  • Squarepoint first reported a position in Iovance Biotherapeutics in Q3 2017 and has held it in 29 quarters since.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.